Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTITUDE long-term real-world prophylaxis study of efanesoctocog alfa in haemophilia A
2024-517812-31-00Phase 4Authorised
- Sponsor
- Sobi
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, open-label, single-arm trial of N-acetyl cysteine + glutathione in hemophilia A, sponsored by Sobi. Primary endpoint: Annualised joint bleeding rate. Planned start May 2025; status: authorised.
02
Drugs
N-acetyl cysteine + glutathione
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2024-517812-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517812-31-00.